Role of adjuvant chemotherapy in patients with early stage uterine papillary serous cancer.
Int. J. Gynecol. Cancer., Nov;21(8):1436-40 (2011)
Fertility preserving options in patients with gynecologic malignancies.
Am. J. Obstet. Gynecol., Aug;205(2):103-10 (2011)
Surgical management of recurrent ovarian cancer: the advantage of collaborative surgical management and a multidisciplinary approach.
Gynecol. Oncol., Jan;120(1):29-32 (2011)
Preoperative diagnosis of ovarian malignancy: preliminary results of the use of 3-dimensional vascular ultrasound.
Int. J. Gynecol. Cancer., Apr;19(3):354-60 (2009)
Sclerosing ductal carcinoma of the clitoris with microcystic adnexal carcinoma-like features.
J. Cutan. Pathol., Mar;36(3):359-61 (2009)
Margin distance and other clinico-pathologic prognostic factors in vulvar carcinoma: a multivariate analysis.
Gynecol. Oncol., Mar;104(3):636-41 (2007)
Influence of serum and tissue micronutrient levels on the regression of untreated cervical intraepithelial neoplasia 2 and 3.
J Low Genit Tract Dis., Oct;6(4):220-4 (2002)
Malignant eccrine spiradenoma of the vulva: a case report and review of the literature.
Int. J. Gynecol. Cancer., 16(3):1465-9 (2006 May-Jun)
The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma.
Gynecol. Oncol., Nov;103(2):679-83 (2006)
Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma.
Int. J. Radiat. Oncol. Biol. Phys., Nov;63(3):839-44 (2005)
Patients with malignancy requiring urgent therapy: CASE 3. Tumor lysis syndrome associated with chemotherapy in ovarian cancer.
J. Clin. Oncol., Sep;23(27):6794-5 (2005)
Clinicopathologic features of six cases of primary cervical lymphoma.
Am. J. Obstet. Gynecol., Sep;193(3 Pt 1):866-72 (2005)
Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma.
Gynecol. Oncol., Sep;98(3):360-8 (2005)
Surgical management of epithelial ovarian cancer: a review of the literature.
Minerva Ginecol., Dec;56(6):547-56 (2004)
Validation of referral guidelines for women with pelvic masses.
Obstet Gynecol., Jan;105(1):35-41 (2005)
Differences in prognostic molecular markers between women over and under 45 years of age with advanced ovarian cancer.
Clin. Cancer Res., Dec;10(24):8538-43 (2004)
Surgical cytoreduction and hormone therapy of an advanced endometrial stromal sarcoma of the ovary.
Obstet Gynecol., May;103(5 Pt 2):1051-4 (2004)
Insulin-like growth factors, insulin-like growth factor-binding proteins, and endometrial cancer in postmenopausal women: results from a U.S. case-control study.
Cancer Epidemiol. Biomarkers Prev., Apr;13(4):607-12 (2004)
Adjuvant radiotherapy following properly staged endometrial cancer: what role?
Gynecol. Oncol., Mar;92(3):737-9 (2004)
Oral altretamine used as salvage therapy in recurrent ovarian cancer.
Gynecol. Oncol., Jan;92(1):368-71 (2004)
Modified technique for suprapubic catheter insertion that avoids urinary leakage.
Am. J. Obstet. Gynecol., Dec;189(6):1670-1 (2003)
Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy.
Am. J. Obstet. Gynecol., Nov;189(5):1301-7 (2003)
Borderline ovarian tumors in reproductive-age women. Fertility-sparing surgery and outcome.
J Reprod Med., Oct;48(10):756-60 (2003)
Malignant germ cell tumors of the ovary.
Obstet Gynecol., Jan;95(1):128-33 (2000)
Interstitial brachytherapy for vaginal recurrences of endometrial carcinoma.
Gynecol. Oncol., Sep;74(3):416-22 (1999)
Interstitial brachytherapy in the treatment of advanced and recurrent vulvar cancer.
Am. J. Obstet. Gynecol., Jul;181(1):91-8 (1999)
Pregnancy in a Jehovah's witness with cervical cancer and anemia.
Gynecol. Oncol., Nov;71(2):330-2 (1998)
Neuroendocrine small cell uterine cervix cancer in pregnancy: long-term survival following combined therapy.
Gynecol. Oncol., Oct;71(1):128-32 (1998)
Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors.
Gynecol. Oncol., Jun;69(3):253-7 (1998)
Cervical cancer with paraaortic metastases: significance of residual paraaortic disease after surgical staging.
Gynecol. Oncol., Jun;69(3):243-7 (1998)
Analysis of histopathological features of endometrioid uterine carcinomas and epidemiologic risk factors.
Cancer Epidemiol. Biomarkers Prev., Mar;7(3):231-5 (1998)
A comparison of intracavitary versus interstitial irradiation in the treatment of cervical cancer.
Gynecol. Oncol., Dec;67(3):241-7 (1997)
Colposcopic regression patterns in high-grade cervical intraepithelial neoplasia.
Obstet Gynecol., Oct;90(4 Pt 1):617-21 (1997)
Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas.
Mod. Pathol., Oct;10(10):963-8 (1997)
Advanced-stage small cell carcinoma of the ovary in pregnancy: long-term survival after surgical debulking and multiagent chemotherapy.
Gynecol. Oncol., Sep;66(3):531-4 (1997)
Intrauterine device use and endometrial cancer risk.
Int J Epidemiol., Jun;26(3):496-500 (1997)
Neither Adam nor Eve seems worth very much anymore.
Gynecol. Oncol., Mar;64(3):369-71 (1997)
Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study.
J. Clin. Oncol., Jan;15(1):165-71 (1997)
A study of biomarkers in cervical carcinoma and clinical correlation of the novel biomarker MN.
Gynecol. Oncol., Dec;63(3):337-44 (1996)
Estrogen replacement in surgical stage I and II endometrial cancer survivors.
Am. J. Obstet. Gynecol., Nov;175(5):1195-200 (1996)
Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer.
J. Natl. Cancer Inst., Oct;88(19):1361-8 (1996)
Case-control study of endogenous steroid hormones and endometrial cancer.
J. Natl. Cancer Inst., Aug;88(16):1127-35 (1996)
Access to cancer care and clinical trials: a time for reappraisal.
Womens Health Issues., 6(2):112-3 (1996 Mar-Apr)
Endometrioid adenocarcinoma of the ovary and its relationship to endometriosis.
Gynecol. Oncol., Oct;59(1):81-6 (1995)
A phase II trial of neoadjuvant chemotherapy prior to radical hysterectomy and/or radiation therapy in the management of advanced carcinoma of the uterine cervix.
Gynecol. Oncol., Oct;59(1):105-10 (1995)
Contracting for professional service agreements.
Gynecol. Oncol., Aug;58(2):159-64 (1995)
Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study.
J. Clin. Oncol., Jul;13(7):1589-99 (1995)
Does perioperative blood transfusion affect survival in patients with cervical cancer treated with radical hysterectomy?
Obstet Gynecol., Mar;85(3):343-8 (1995)
Spontaneous release of interleukin-6 by primary cultures of lymphoid and tumor cell populations purified from human ovarian carcinoma.
J. Interferon Cytokine Res., Mar;15(3):255-60 (1995)
Comparison of the polymerase chain reaction and Southern blot analysis in detecting and typing human papilloma virus deoxyribonucleic acid in tumors of the lower female genital tract.
Diagn. Mol. Pathol., Dec;3(4):283-91 (1994)
Primary vaginal melanoma: improved survival with radical pelvic surgery.
Gynecol. Oncol., Nov;55(2):234-7 (1994)
Cost analysis of Hickman catheter insertion at bedside in gynecologic oncology patients.
J. Am. Coll. Surg., Nov;179(5):558-60 (1994)
Endometrial cancer risk in relation to serum lipids and lipoprotein levels.
Cancer Epidemiol. Biomarkers Prev., 3(7):575-81 (1994 Oct-Nov)
Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas.
Am. J. Pathol., Sep;145(3):598-609 (1994)
A new method of continuous vaginal cuff closure at abdominal hysterectomy.
Obstet Gynecol., Sep;84(3):478-80 (1994)
Extent of disease as an indication for pelvic radiation following radical hysterectomy and bilateral pelvic lymph node dissection in the treatment of stage IB and IIA cervical carcinoma.
Gynecol. Oncol., Jul;54(1):4-9 (1994)
Adhesions after extensive gynecologic surgery: clinical significance, etiology, and prevention.
Am. J. Obstet. Gynecol., May;170(5 Pt 1):1396-403 (1994)
Cyclosporin enhancement of cisplatin chemotherapy in patients with refractory gynecologic cancer. A Gynecologic Oncology Group Study.
Cancer., Jan;73(1):196-9 (1994)
Moderate alcohol consumption and the risk of endometrial cancer.
Epidemiology., Nov;4(6):530-6 (1993)
To drain or not to drain: a retrospective study of closed-suction drainage following radical hysterectomy with pelvic lymphadenectomy.
Gynecol. Oncol., Oct;51(1):46-9 (1993)
Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary.
Gynecol. Oncol., Sep;50(3):347-51 (1993)
Past and present physical activity and endometrial cancer risk.
Br. J. Cancer., Sep;68(3):584-9 (1993)
Relation of endometrial cancer risk to past and contemporary body size and body fat distribution.
Cancer Epidemiol. Biomarkers Prev., 2(4):321-7 (1993 Jul-Aug)
Oral contraceptives and endometrial cancer: do other risk factors modify the association?
Int. J. Cancer., May;54(2):243-8 (1993)
Dietary associations in a case-control study of endometrial cancer.
Cancer Causes Control., May;4(3):239-50 (1993)
Cigarette smoking and the risk of endometrial cancer.
Am. J. Epidemiol., Feb;137(3):281-91 (1993)
Expression of human recombinant 72 kDa gelatinase and tissue inhibitor of metalloproteinase-2 (TIMP-2): characterization of complex and free enzyme.
Biochem. J., Jan;289 ( Pt 2):411-6 (1993)
Surgical treatment of unexpected invasive cervical cancer found at total hysterectomy.
Obstet Gynecol., Dec;80(6):931-4 (1992)
Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study.
Am. J. Obstet. Gynecol., Nov;167(5):1317-25 (1992)
Bulky stage IB cervical carcinoma managed by primary radical hysterectomy followed by tailored radiotherapy.
Gynecol. Oncol., Oct;47(1):21-7 (1992)
Domain structure of human 72-kDa gelatinase/type IV collagenase. Characterization of proteolytic activity and identification of the tissue inhibitor of metalloproteinase-2 (TIMP-2) binding regions.
J. Biol. Chem., Aug;267(22):15398-405 (1992)
Effects of early postoperative chemotherapy on wound healing.
Obstet Gynecol., Jun;79(6):988-92 (1992)
Immunotherapy of ovarian cancer. II. In vitro generation and characterization of lymphokine-activated killer T cells from the peripheral blood of recurrent ovarian cancer patients.
Gynecol. Oncol., May;45(2):129-35 (1992)
Radiation myelitis: a complication of concurrent cisplatin and 5-fluorouracil chemotherapy with extended field radiotherapy for carcinoma of the uterine cervix.
Gynecol. Oncol., Dec;43(3):305-8 (1991)
Early evaluation of the urinary tract following radical hysterectomy: structure and function relationships.
Obstet Gynecol., Nov;78(5 Pt 1):840-4 (1991)
Unusual metastases from a malignant melanoma. A case report.
J Reprod Med., Sep;36(9):688-90 (1991)
CA 125 regression: a model for epithelial ovarian cancer response.
Am. J. Obstet. Gynecol., Aug;165(2):360-7 (1991)
Clinical and histologic features of vulvar carcinomas analyzed for human papillomavirus status: evidence that squamous cell carcinoma of the vulva has more than one etiology.
Hum. Pathol., Jul;22(7):711-8 (1991)
Paraneoplastic hypercalcemia associated with adenosquamous carcinoma of the endometrium.
Gynecol. Oncol., Jan;40(1):95-8 (1991)
Use of vaginal hysterectomy for the management of stage I endometrial cancer in the medically compromised patient.
Gynecol. Oncol., Jan;40(1):74-7 (1991)
Does intraperitoneal CA-125 reflect disease status?
Gynecol. Oncol., Jan;40(1):66-9 (1991)
Influence of histological features and treatment on the prognosis of patients with cervical cancer metastatic to pelvic lymph nodes.
Gynecol. Oncol., Nov;39(2):127-31 (1990)
Hemolytic-uremic syndrome associated with neoadjuvant chemotherapy in the treatment of advanced cervical cancer.
Gynecol. Oncol., Nov;39(2):214-7 (1990)
Primary invasive carcinoma of the vagina.
Obstet Gynecol., Oct;76(4):639-42 (1990)
The use of molecular probes to distinguish new primary tumors from recurrent tumors in gynecologic malignancies.
Am. J. Clin. Pathol., Oct;94(4):432-4 (1990)